TY - JOUR
T1 - Incidence of secondary neoplasms in patients with acute promyelocytic leukemia treated with all-trans retinoic acid plus chemotherapy or with all-trans retinoic acid plus arsenic trioxide
AU - Eghtedar, Alireza
AU - Rodriguez, Ildefonso
AU - Kantarjian, Hagop
AU - O'Brien, Susan
AU - Daver, Naval
AU - Garcia-Manero, Guillermo
AU - Ferrajoli, Alessandra
AU - Kadia, Tapan
AU - Pierce, Sherry
AU - Cortes, Jorge
AU - Ravandi, Farhad
N1 - Publisher Copyright:
© 2014 Informa UK, Ltd.
PY - 2015/5/1
Y1 - 2015/5/1
N2 - The incidence and pattern of secondary neoplasms in patients with acute promyelocytic leukemia (APL) treated with all-trans retinoic acid (ATRA)-containing regimens is not well described. We compared 160 patients with APL treated with ATRA plus idarubicin (n = 54) or ATRA plus arsenic trioxide (ATO) (n = 106) for the incidence of secondary cancers per unit time of follow-up. Median follow-up times for the two cohorts were 136 and 29 months, respectively. Nine patients developed secondary cancers in the chemotherapy group. These included two breast cancers, three myelodysplastic syndromes/acute myeloid leukemia, one vulvar cancer, one prostate cancer, one colon cancer and one soft tissue sarcoma. A melanoma and one pancreatic cancer developed in the ATO group. We conclude that treatment of patients with APL using the non-chemotherapy regimen of ATRA plus ATO is not associated with a higher incidence of secondary cancers (p = 0.29) adjusted for unit time of exposure.
AB - The incidence and pattern of secondary neoplasms in patients with acute promyelocytic leukemia (APL) treated with all-trans retinoic acid (ATRA)-containing regimens is not well described. We compared 160 patients with APL treated with ATRA plus idarubicin (n = 54) or ATRA plus arsenic trioxide (ATO) (n = 106) for the incidence of secondary cancers per unit time of follow-up. Median follow-up times for the two cohorts were 136 and 29 months, respectively. Nine patients developed secondary cancers in the chemotherapy group. These included two breast cancers, three myelodysplastic syndromes/acute myeloid leukemia, one vulvar cancer, one prostate cancer, one colon cancer and one soft tissue sarcoma. A melanoma and one pancreatic cancer developed in the ATO group. We conclude that treatment of patients with APL using the non-chemotherapy regimen of ATRA plus ATO is not associated with a higher incidence of secondary cancers (p = 0.29) adjusted for unit time of exposure.
KW - Arsenic
KW - Leukemia
KW - Promyelocytic
KW - Secondary neoplasm
UR - http://www.scopus.com/inward/record.url?scp=84932153505&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84932153505&partnerID=8YFLogxK
U2 - 10.3109/10428194.2014.953143
DO - 10.3109/10428194.2014.953143
M3 - Article
C2 - 25120050
AN - SCOPUS:84932153505
SN - 1042-8194
VL - 56
SP - 1342
EP - 1345
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 5
ER -
